📏 Familial Short Stature Genetic Target Height Simulator

Measuring the Foundation — Accurate Parental Height Data Collection

Every downstream calculation in this simulator — the mid-parental target, the percentile comparison, the clinical decision — depends entirely on two numbers being correct: the biological father's and mother's actual adult height. Getting those numbers right is not a formality. Self-reported height, rounded estimates, or heights measured with shoes on can shift a target height calculation by several centimeters, enough to turn a reassuring concordant case into a false alarm, or worse, mask a real pathology.

• <0.5 cm: Stadiometer measurement error (calibrated wall-mounted device)
• +2.5 cm: Self-reported height bias (average adult over-estimate)
• 1–2 cm: Diurnal height variation (taller in morning, disc compression)
• Both: Biological parent required (not step-parents or estimates)

Why measured height, not self-report, matters

Target height calculations are exquisitely sensitive to input precision. Because the mid-parental formula divides the sum of two heights by two, a 2cm overestimate in each parent translates directly into a 2cm shift in the calculated target — and a shift in target percentile that can span 5–10 percentile points on a growth chart.

Proper protocol: • Parent stands barefoot, heels together, against a calibrated stadiometer (not a tape measure on a wall, not a self-estimate) • Measurement taken in the morning when possible, since intervertebral disc compression over the day can reduce height by 1–2cm • Two independent measurements averaged; a third taken if they differ by more than 0.3cm • Documented in the chart with date and method — "reported" heights are flagged and, where feasible, re-measured at a subsequent visit

Studies comparing self-reported to measured adult height consistently find that shorter individuals tend to overestimate their height more than taller individuals, and men overestimate slightly more than women — a bias pattern that would systematically distort target height calculations if left uncorrected.

A single un-measured, self-reported parental height is the single most common source of error in pediatric growth genetics — correct it before doing any calculation, not after a discordant result raises alarm.

Correcting for parental growth-affecting conditions

Not every short parent is short for purely polygenic, familial reasons. Before a parent's measured height is accepted at face value for the target height calculation, the clinician should screen for conditions that would make that height an unreliable genetic reference point:

• Untreated childhood growth hormone deficiency or hypothyroidism in a parent — their adult height reflects a treatable illness, not their true genetic potential • Skeletal dysplasias (achondroplasia, hypochondroplasia) — disproportionate short stature with a distinct inheritance pattern that should be evaluated separately, not averaged into a standard mid-parental formula • Severe childhood malnutrition or chronic disease (celiac disease, inflammatory bowel disease) that blunted a parent's own growth • Significant kyphoscoliosis or vertebral compression in an older parent, which can shave several centimeters off a standing height measurement that no longer reflects skeletal genetic potential

When such a condition is identified, many clinicians will use the parent's estimated pre-morbid or corrected height, or flag the mid-parental calculation as less reliable and weight the clinical picture — bone age, growth velocity, physical exam — more heavily than the formula alone.

Calculating the Mid-Parental Target Height — The Genetic Height Blueprint

With accurate parental heights in hand, the mid-parental target height formula converts two numbers into a single genetically expected adult height for the child, plus a statistically defined range of normal. This simple arithmetic, first popularized by Tanner in the 1970s, remains the backbone of every pediatric growth evaluation worldwide — a fast, free, first-pass filter before any laboratory test is ordered.

• (F+M+13)/2: Boys formula (centimeters, +13cm sex adjustment)
• (F+M−13)/2: Girls formula (centimeters, −13cm sex adjustment)
• ±8.5 cm: Target range (±2SD) (covers ~95% of expected outcomes)
• ~80%: Heritability of adult height (twin & family studies)

Where the +13cm / −13cm adjustment comes from

Adult men are, on population average, roughly 13cm taller than adult women — a sex-dimorphism driven by differences in pubertal growth spurt timing and duration, and by the growth-promoting and growth-limiting effects of estrogen versus testosterone on the growth plate.

The mid-parental formula first averages the two parents' heights — this represents the "family average" independent of the child's sex — then adjusts that average by half the population male-female height gap (13cm) in the appropriate direction depending on whether the child is a boy or a girl:

Boys: Target = (Father's height + Mother's height + 13) / 2 Girls: Target = (Father's height + Mother's height − 13) / 2

Worked example: father 178cm, mother 165cm. • Son's target: (178 + 165 + 13) / 2 = 178cm • Daughter's target: (178 + 165 − 13) / 2 = 165cm

The formula essentially asks: "if this child inherited an average blend of both parents' height genes, and grew up experiencing typical nutrition and health, what height would they reach — adjusted for whether they will go through a male or female puberty?"

The ±8.5cm target range and what it means statistically

Height is a polygenic trait influenced by hundreds of common genetic variants plus environmental factors (nutrition, chronic illness, socioeconomic conditions), and heritability studies estimate that roughly 80% of the variance in adult height within a population is attributable to genetics.

Because the mid-parental estimate is just that — an estimate, not a certainty — it comes with a statistically derived confidence range. The commonly used range is ±2 standard deviations (2SD), which for height translates to approximately ±8.5cm (some references use ±10cm as a rounder, slightly more conservative figure). This range is designed to capture roughly 95% of children born to parents of the given heights, accounting for the normal biological variation in exactly which combination of height-associated alleles a given child inherits, plus environmental influences on final adult stature.

A child whose own eventual adult height, or growth-chart trajectory, falls anywhere within Target ± 8.5cm (Target Height Percentile roughly 3rd–97th percentile of the family-adjusted distribution) is generally considered to be growing within their expected genetic potential — even if that potential happens to be on the shorter side of population norms.

The mid-parental target height is a population-derived estimate, not a guarantee — roughly 1 in 20 children will fall genuinely outside the ±8.5cm range for entirely normal reasons, which is exactly why it is combined with growth velocity and clinical judgment rather than used in isolation.

Plotting Genetic Potential Against Current Growth — Concordance or Red Flag?

A target height number is only useful once it is placed in context against where the child actually is right now. This stage converts the mid-parental target into a target height percentile on the standard population growth chart, then compares it directly against the child's own current height percentile. The size of the gap between these two percentiles is the single most informative number in distinguishing a normal genetic variant from a growth disorder.

• ~10 %ile: Concordance threshold (gap considered within normal noise)
• ~20–25%: Familial short stature prevalence (of all short-stature referrals)
• CDC / WHO: Growth chart standard (age- and sex-specific percentile curves)
• ≈ chronological: Bone age in FSS (unlike constitutional delay, GH deficiency)

Converting target height to a percentile, and why that matters more than the raw centimeters

A target height of, say, 168cm means very different things depending on the child's sex and the population reference. Converting that raw number to a percentile — "this target height sits at roughly the 20th percentile for adult male height" — puts it on the same scale as the child's own growth chart, where their current height is already tracked as, for instance, "18th percentile for a 9-year-old boy."

Once both numbers live on the same percentile scale, the comparison becomes direct and visual: does the child's current percentile fall inside the target height percentile's expected band, or well outside it?

This reframing is clinically powerful because it separates two very different questions that are easy to conflate: • "Is this child short?" (a comparison to the general population) • "Is this child shorter than we would expect GIVEN THEIR PARENTS?" (a comparison to their own genetic potential)

A child at the 10th percentile with parents whose target height also sits around the 10th percentile is growing exactly as genetically expected. A child at the 10th percentile with a target height at the 60th percentile is a very different, more concerning picture.

Concordant vs. discordant patterns — what the gap tells you

Concordant pattern (familial short stature, a normal variant): • Child's current percentile sits close to (generally within about 10 percentile points, or within the ±8.5cm target range) the calculated target height percentile • Growth curve has been stable along that same percentile channel since early childhood — not falling further away over time • Physical exam is otherwise unremarkable; bone age approximates chronological age • Interpretation: this child's height reflects their genetic inheritance, not disease — reassurance is appropriate

Discordant pattern (possible pathologic growth failure): • Child's current percentile is well below the target height percentile — for example, a child at the 3rd percentile whose parents predict a target around the 50th percentile • The growth curve may show crossing of percentile lines downward over time, rather than steady tracking • May be accompanied by other clinical clues: abnormal proportions, dysmorphic features, systemic symptoms, delayed bone age far behind chronological age, or bone age far advanced • Interpretation: the gap between genetic potential and actual growth is not explained by heredity alone — an underlying medical cause should be actively sought

The percentile comparison does not, by itself, diagnose anything — but it efficiently sorts the large majority of short children (who are short because their parents are short) from the minority who need further evaluation.

Roughly 80% of children evaluated for short stature turn out to have either familial short stature or constitutional delay of growth and puberty — both normal variants. The target-height comparison is what lets clinicians confidently reassure that majority while still catching the minority who need real workup.

Growth Velocity — The Key Discriminator Between Normal Variant and Pathology

A single height measurement is a snapshot; growth velocity is the movie. Even when a child's current percentile looks concerning in isolation, the rate at which they are growing — centimeters gained per year, plotted over successive visits — is often the single most decisive piece of evidence separating benign familial short stature from a genuine growth disorder, because it directly reflects whether the growth plates are functioning normally over time.

• 5–6 cm/yr: Normal prepubertal velocity (ages ~3 through puberty onset)
• Normal: Familial short stature velocity (tracks percentile, does not fall)
• <4 cm/yr: Pathologic deceleration flag (prepubertal, sustained over 6–12mo)
• ≥ 6 months: Minimum interval to assess (to average out measurement noise)

Why velocity beats a single height measurement

Height percentile at any one moment tells you where a child stands relative to peers; it cannot, by itself, tell you whether that position is stable, improving, or actively worsening. Two children can share the exact same height percentile today and be on completely different trajectories — one has always tracked that percentile since toddlerhood (stable, likely genetic), the other was at the 50th percentile a year ago and has been steadily falling (concerning, likely pathologic).

Growth velocity — typically expressed in centimeters per year, calculated from at least two measurements taken 6–12 months apart on a calibrated stadiometer — converts the static snapshot into a trend. Plotted on a growth velocity chart (a less commonly used but highly informative complement to the standard height-for-age chart), a child's velocity should itself sit within a normal percentile band for their age.

Measurement pitfalls to avoid: • Intervals shorter than 6 months amplify measurement noise (a few millimeters of technique variation) into an apparently dramatic velocity change • Different stadiometers or different measurers between visits can introduce systematic offsets • Velocity naturally varies with pubertal stage — a pubertal growth spurt is expected to accelerate velocity well above the prepubertal baseline, and comparing across that transition without adjustment is misleading

Normal familial short stature velocity vs. pathologic deceleration

Familial short stature — the reassuring pattern: • Growth velocity runs at a normal rate for age (roughly 5–6cm/year in the mid-childhood years, following the expected pubertal acceleration and deceleration pattern at the appropriate age) • The child is simply growing along a lower percentile channel — genetically consistent with shorter parents — but that channel is stable, not falling further away from the population median over time • Bone age tracks close to chronological age, and puberty begins at a typical age • Because the growth plates are functioning normally and simply "programmed" for a shorter genetic ceiling, no medical intervention changes the outcome

Pathologic growth failure — the red-flag pattern: • Growth velocity is below the normal range for age and pubertal stage — often below the 25th percentile for velocity, or an absolute rate under about 4cm/year in a prepubertal child sustained over 6–12 months • The height percentile actively crosses downward across major percentile lines over successive visits, rather than tracking a stable channel • Underlying causes to consider include growth hormone deficiency, hypothyroidism, chronic systemic disease (celiac disease, inflammatory bowel disease, chronic kidney disease), skeletal dysplasia, Turner syndrome, or psychosocial/nutritional growth failure • This pattern warrants laboratory and imaging workup regardless of how the target-height percentile comparison looked, because deceleration is itself diagnostic of a process actively suppressing growth

The clinical rule of thumb: a low but STABLE percentile with normal velocity is reassuring; a percentile that is FALLING, or a velocity below the age-appropriate normal range, is a red flag that overrides an otherwise reassuring target-height comparison and merits further workup.

Genetic Counseling, Reassurance, or Endocrine Workup — Translating Data into Care

The target height calculation, the percentile comparison, and the velocity trend all converge on this final decision point: does this child need reassurance and routine monitoring, or a full diagnostic workup? Getting this decision right avoids two opposite harms — over-medicalizing a normal genetic variant with unnecessary tests and ineffective therapy, or under-investigating a treatable growth disorder while precious growth-plate time is lost.

• Minimal: GH therapy efficacy in FSS (not indicated for normal variant)
• SHOX, skeletal: Discordant workup panel (dysplasia gene panels, karyotype)
• ±4–6 cm: Predicted adult height accuracy (Bayley-Pinneau bone-age method)
• Annual: Concordant follow-up interval (routine growth monitoring only)

Concordant familial short stature — reassurance, not treatment

When the child's current percentile is concordant with the mid-parental target height percentile, and growth velocity has been consistently normal, the evidence strongly supports a diagnosis of familial (genetic) short stature — a normal variant, not a disease.

What this means for management: • No laboratory testing is required beyond what routine well-child care already recommends • Growth hormone therapy is not indicated: multiple clinical trials have shown that GH treatment in children with normal GH secretion and familial short stature produces only a modest, often clinically insignificant increase in adult height (frequently just a few centimeters, well within measurement and estimation error), while adding cost, daily injections, and a real if small side-effect burden • Genetic counseling focuses on explaining the mid-parental target height concept to the family in plain terms: this height reflects normal inheritance, similar to eye color or build, and is not a sign that something is wrong • Continued routine annual growth monitoring is still appropriate — familial short stature is a working diagnosis that should be revisited if the growth pattern later changes (deceleration, unexpected percentile crossing)

This reassurance is not merely emotionally comforting — it is evidence-based medicine, sparing the family unnecessary anxiety, cost, and medicalization of a normal trait.

Growth hormone is one of the most studied pediatric therapies, and the data are consistent: in children who are short but have normal GH secretion and a target height that matches their trajectory, GH therapy is not FDA-approved for this indication in most cases and yields minimal height benefit — the strongest argument for accurate diagnosis before any treatment decision.

Discordant cases — proceeding to full endocrine and genetic workup

When the child's percentile is well below the calculated target, and/or growth velocity is abnormal or decelerating, the picture is discordant with simple familial inheritance, and a structured workup is warranted:

Initial laboratory screen: • Complete blood count, comprehensive metabolic panel, ESR/CRP — screen for chronic systemic disease • Celiac disease serologies (tissue transglutaminase IgA) — a frequently under-recognized cause of growth failure • Thyroid function tests (TSH, free T4) — hypothyroidism directly suppresses growth velocity • IGF-1 and IGFBP-3 — screening markers for growth hormone axis function • Bone age radiograph (left hand/wrist) — compares skeletal maturation to chronological age, informs predicted adult height

Targeted genetic and endocrine evaluation, guided by clinical features: • Karyotype in girls with unexplained short stature — screens for Turner syndrome (45,X), which is easily missed without dysmorphic features • SHOX gene analysis — mutations or deletions cause disproportionate short stature (Léri-Weill dyschondrosteosis) and can be subtle • Skeletal dysplasia gene panels when body proportions are abnormal (short limbs relative to trunk, or vice versa) • Formal growth hormone stimulation testing if IGF-1/IGFBP-3 are low and clinical suspicion for GH deficiency is present • Referral to pediatric endocrinology for cases that remain unexplained after initial screening

The genetic counseling conversation here is different in tone from the concordant case: it explains that the growth pattern does not match what would be expected from the parents' heights alone, and that finding the underlying cause matters because some of these conditions (GH deficiency, hypothyroidism, celiac disease) are treatable, with better outcomes the earlier they are identified — while growth plates are still open.